Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
100 participants
INTERVENTIONAL
2013-05-31
2015-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Aim: To compare the results of frozen thawed embryo transfers with and without GnRHa analogue support Primary end point: IR, PR, on going PR Secondary end point: hCH, E2 and progesterone levels 14 days after thawing
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Natural cycle, control
Treatment cycles with normal luteal support with progesteron
No interventions assigned to this group
Natural cycle, intervention
Treatment cycles with normal luteal support with progesteron and a single dose of 0.1 mg triptorelin when the age of the embryo was 6 days: Intervention is the additional 0.1 mg triptorelin as described in the previous sentence.
Natural cycle: Triptorelin acetate 0.1 mg
A single dose of triptorelin acetate 0.1 s.c. was giwen when the age of the transferred embryo was six days in additon to standard micronized progesterone 400 mg vaginally
Hormone replacement cycle, control
Standard hormone replacement cycle with estrogen and progesteron
No interventions assigned to this group
Hormone replacement cycle, intervention
Standard hormone replacement cycle with estrogen and progesteron and a single dose of 0.1 mg triptorelin when the age of the embryo was 6 days
Natural cycle: Triptorelin acetate 0.1 mg
A single dose of triptorelin acetate 0.1 s.c. was giwen when the age of the transferred embryo was six days in additon to standard micronized progesterone 400 mg vaginally
Hormone replacement cycle and triptorelin acetate 0.1 mg
A single dose of triptorelin acetate 0.1 s.c. was giwen when the age of the transferred embryo was six days in addition to standard Estradiol and progesterone support
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Natural cycle: Triptorelin acetate 0.1 mg
A single dose of triptorelin acetate 0.1 s.c. was giwen when the age of the transferred embryo was six days in additon to standard micronized progesterone 400 mg vaginally
Hormone replacement cycle and triptorelin acetate 0.1 mg
A single dose of triptorelin acetate 0.1 s.c. was giwen when the age of the transferred embryo was six days in addition to standard Estradiol and progesterone support
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Abnormal uterus
* Known abnormality of karyotype of the woman or her partner
* Severe male factor as an exclusive reason for subfertility
* Allegy for triptorelin acetate
20 Years
45 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Turku University Hospital
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Varpu Jokimaa, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Hospital District of the South-West Finland
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
T5/2013
Identifier Type: -
Identifier Source: org_study_id